Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Publication
, Journal Article
Othus, M; Thomas, I; Wang, X; Ariti, C; Mehta, P; Sydenham, M; Hills, RK; Burnett, AK; Nand, S; Assouline, S; Michaelis, LC; Erba, HP ...
Published in: Leuk Lymphoma
January 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Leuk Lymphoma
DOI
EISSN
1029-2403
Publication Date
January 2023
Volume
64
Issue
1
Start / End Page
250 / 252
Location
United States
Related Subject Headings
- Prognosis
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Disease-Free Survival
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Othus, M., Thomas, I., Wang, X., Ariti, C., Mehta, P., Sydenham, M., … Dennis, M. (2023). Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leuk Lymphoma, 64(1), 250–252. https://doi.org/10.1080/10428194.2022.2131416
Othus, Megan, Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham, Robert K. Hills, et al. “Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.” Leuk Lymphoma 64, no. 1 (January 2023): 250–52. https://doi.org/10.1080/10428194.2022.2131416.
Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M, et al. Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leuk Lymphoma. 2023 Jan;64(1):250–2.
Othus, Megan, et al. “Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.” Leuk Lymphoma, vol. 64, no. 1, Jan. 2023, pp. 250–52. Pubmed, doi:10.1080/10428194.2022.2131416.
Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M, Hills RK, Burnett AK, Nand S, Assouline S, Michaelis LC, Erba HP, Russell N, Kerr KF, Walter RB, Dennis M. Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leuk Lymphoma. 2023 Jan;64(1):250–252.
Published In
Leuk Lymphoma
DOI
EISSN
1029-2403
Publication Date
January 2023
Volume
64
Issue
1
Start / End Page
250 / 252
Location
United States
Related Subject Headings
- Prognosis
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Disease-Free Survival
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences